AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land
AbbVie shares were flat after-hours Monday following a three-year TrumpRx pricing deal tied to tariff exemptions. The company also licensed a cancer drug from China’s RemeGen for $650 million upfront and agreed to buy a device plant in Tempe. AbbVie closed at $220.04, down less than 0.1%. Details on the pricing agreement remain limited.